Zygomatico-orbital intra-arterial melphalan infusion for intraocular retinoblastoma
- Department of Radiology and Biomedical Imaging, University California San Francisco, San Francisco, California, USA
- Correspondence to Dr Daniel Cooke, Department of Radiology and Biomedical Imaging, University California San Francisco, 505 Parnassus Avenue, San Francisco, California, USA;
Contributors RH, CD, HF and WK helped with the production and review of the manuscript. DC and VH, in addition to the assisting in production of the manuscript, were the primary operators for the case described.
- Received 8 March 2011
- Revised 19 June 2011
- Accepted 21 June 2011
- Published Online First 11 July 2011
Retinoblastoma is a rare and curable malignancy affecting the pediatric population. For advanced stage intraocular retinoblastoma, enucleation remains the primary treatment modality, although the use of laser photocoagulation, cryotherapy, radiotherapy and chemotherapy are frequently used, particularly in the setting of bilateral disease. Intravenous chemotherapy is the long-standing method of delivery, but local administration (subtenon, intravitreal or intra-arterial) is gaining in popularity because of the reduced side effects related to systemic administration. Of these newer methods, intra-arterial infusion has demonstrated technical feasibility, few procedural complications and robust tumor response. A case is described where a collateral supply to the affected ophthalmic artery was via the zygomatico-orbital branch of the ipsilateral superficial temporal artery. Melphalan infusion was performed via this pathway without incident.
Competing interests None.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.